The Next Generation of Cardiac Device Power: Advances in Battery Replacement and Rechargeability

Cardiac implantable electronic devices (CIEDs) — including pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy (CRT) systems — have transformed the management of arrhythmias, heart failure, and sudden cardiac death. For decades, the Achilles’ heel of these life-saving devices has been their power source. Conventional lithium-based batteries offer a finite lifespan, typically five to fifteen years, after which the entire device must be surgically explanted and replaced. That replacement procedure carries risks of infection, bleeding, lead damage, and increased healthcare costs, and it can erode patient quality of life. But a wave of emerging technologies promises to change this paradigm. From wireless recharging systems that eliminate the need for surgery to energy-harvesting mechanisms that draw power from the body itself, the future of cardiac device power is rapidly evolving.

This article explores the most promising innovations in cardiac device battery replacement and rechargeability — including inductive charging, piezoelectric energy harvesting, biocompatible micro-batteries, and ultrasonic power transfer — and examines how these technologies could reduce morbidity, extend device longevity, and improve patient outcomes.

Current Challenges with Conventional Cardiac Device Batteries

The standard battery used in pacemakers and ICDs is a lithium-iodine or lithium-silver vanadium oxide cell. While these chemistries offer high energy density and reliable performance, they are designed as primary (non-rechargeable) cells. Once the battery reaches end-of-life — indicated by a decline in voltage or a specific elective replacement indicator — the patient must undergo a replacement procedure. In the United States alone, more than 300,000 CIED generator replacements are performed each year. The cost of a single replacement procedure can exceed $30,000 when factoring in hospital stay, surgeon fees, and device costs.

Beyond financial burden, repeated surgery increases the risk of complications. A large registry study found that generator replacement carries a 4–7% risk of major adverse events, including infection, hematoma, and lead dislodgement. For patients with multiple comorbidities, each additional operation heightens the chance of morbidity. Moreover, battery depletion can be unpredictable; patients may experience significant anxiety as their device approaches its recommended replacement interval. The psychological toll of “battery anxiety” and the logistical challenge of scheduling surgery before depletion are significant concerns.

Additionally, the environmental footprint of discarded pacemaker generators — containing metals, electronics, and toxic materials — is growing as the number of implanted devices rises. A more sustainable, rechargeable approach would benefit both patients and healthcare systems.

Wireless Charging Technologies for Implantable Devices

One of the most actively investigated solutions is wireless power transfer (WPT). By avoiding direct electrical contacts or penetrating wires, WPT systems can recharge the device’s internal battery through intact skin. Several modalities are under development.

Inductive Coupling

Inductive charging uses a pair of loosely coupled coils: an external transmitting coil placed on the skin surface and a receiving coil embedded inside the device. Alternating current in the external coil generates a magnetic field that induces voltage in the implant coil. This technology is already used in consumer electronics (e.g., smartphone charging pads) and in some medical implants, such as cochlear implants and ventricular assist devices. For cardiac devices, inductive charging can deliver several watts of power across a distance of a few centimeters.

Researchers have demonstrated transcutaneous inductive charging systems for pacemakers that can recharge a battery from 20% to full capacity in about two hours. The external charger can be worn as a patch or placed over the implant site during sleep. Key challenges include maintaining alignment between coils (patient movement can reduce efficiency), managing heat generation to avoid tissue damage, and ensuring that the external charger does not interfere with device sensing or pacing functions. Modern designs incorporate closed-loop control to adjust power levels in real time, keeping tissue heating within safe limits.

Ultrasonic Power Transfer

An alternative to magnetic fields is ultrasonic energy transmission. High-frequency sound waves (above human hearing) can travel through tissue and be converted to electrical energy via a piezoelectric receiver inside the device. Ultrasonic systems can be more compact than inductive coils and do not suffer from the same alignment sensitivity. They also present minimal risk of electromagnetic interference with other medical equipment.

Recent animal studies have shown ultrasonic recharging of miniature pacemaker batteries with efficiency approaching 10–15% — lower than inductive coupling but still sufficient to trickle-charge a battery over extended periods. The primary hurdle is that ultrasound attenuates significantly as it passes through bone and air pockets (e.g., lung tissue), so the implant location must be carefully chosen. For submuscular or subcutaneous devices, ultrasonic charging may prove viable, especially for devices with low power consumption, such as leadless pacemakers.

Mid-Field and Far-Field Electromagnetic Transfer

Researchers at Stanford and other institutions have developed “mid-field” wireless power systems that use propagating electromagnetic waves in the tens to hundreds of megahertz range. These waves — unlike near-field inductive fields — can travel through heterogeneous tissue and can be focused using a phased-array external antenna. The internal receiver is a tiny antenna (a few millimeters in size) that can be integrated into the device’s casing. In a 2014 milestone, a prototype was used to power a customized pacemaker in a pig, marking the first demonstration of deep-tissue wireless power transfer for cardiac applications. Further refinements have improved efficiency and reduced the size of the external transmitter.

While mid-field technology remains largely preclinical, it offers the tantalizing possibility of a “wearable charger” that can automatically recharge an implant while the patient sleeps or goes about daily activities, without requiring precise alignment.

Energy Harvesting: Powering Devices from the Body

Rather than relying on intermittent external recharging, energy-harvesting technologies aim to capture energy from physiological processes to continuously top off the device’s battery — or even to power it indefinitely without a battery at all. The most common sources are mechanical motion, thermal gradients, and biofluid flow.

Piezoelectric Energy Harvesting from Cardiac Motion

Piezoelectric materials generate an electric charge when subjected to mechanical stress. For cardiac applications, the periodic contraction and relaxation of the heart muscle provides a ready source of vibration and deformation. Integrating a thin piezoelectric film or a cantilever structure onto the device’s outer shell or attaching it to the myocardium can convert these mechanical pulses into electrical current.

In a notable 2019 study, engineers developed a flexible piezoelectric device that could be wrapped around the heart’s surface, generating enough power to run a pacemaker under realistic conditions. Output power density reached approximately 0.5–1 µW/cm², which is sufficient for a low-power pacemaker (typically consuming 5–10 µW). The challenge lies in long-term biocompatibility: the material must remain flexible enough to avoid impeding cardiac motion and must not trigger inflammation or fibrosis that would degrade its performance over years.

Triboelectric Nanogenerators (TENGs)

Triboelectric generators harvest energy from contact electrification — the charge transfer that occurs when two different materials touch and separate. In the body, heartbeats and even breathing can drive such relative motion. TENGs can be fabricated from biocompatible silicone and metals, and they have been shown to produce peak power densities of tens of microwatts per square centimeter. A 2021 paper demonstrated a fully implantable TENG-based pacemaker in a large animal model that could maintain pacing without a battery for short periods. However, TENGs typically produce high-voltage, low-current pulses that require power electronics to regulate and store energy; the electronics themselves consume power, reducing net gains.

Thermoelectric Harvesting

The human body maintains a core temperature of ~37°C while the skin surface is often 10–15°C cooler under normal ambient conditions. That temperature difference can be exploited by thermoelectric generators (TEGs) that convert heat flow into electricity via the Seebeck effect. For subcutaneous implants, the temperature gradient may be only a few degrees, yielding extremely small voltages. However, a TEG integrated into a pacemaker can trickle-charge a supercapacitor or battery at rates of 1–5 µW — enough to offset the self-discharge of the battery or to power sensing circuits. Researchers at the University of Washington have developed a flexible TEG that can wrap around a pacemaker can, generating roughly 2.2 µW at a 2°C gradient. While inadequate to fully power a pacing device, significant advances in thermoelectric materials (such as bismuth telluride alloys and organic thermoelectrics) could push output to clinically useful levels.

Rechargeable Battery Architectures for Implants

Even with wireless charging or energy harvesting, a rechargeable energy storage element is still needed to buffer power during periods of inactivity or high demand (e.g., during defibrillation). Lithium-ion and lithium-polymer batteries have been the standard for rechargeable medical devices (e.g., neurostimulators, insulin pumps), but their use in cardiac devices has been limited by concerns over safety, cycle life, and volumetric energy density.

Biocompatible Microbatteries

Recent advances in solid-state batteries offer a promising route. Solid-state lithium batteries replace the flammable liquid electrolyte with a solid ceramic or polymer electrolyte, greatly enhancing safety. They are less prone to leakage, dendrite formation, and thermal runaway. Moreover, solid-state designs can be made extremely thin and flexible, conforming to the curved surfaces of a pacemaker can or leadless capsule. Companies such as Cymbet, Ilika, and TDK are developing micro‑solid-state batteries with capacities of several milliampere-hours — enough to power a leadless pacemaker for weeks between charging cycles. These batteries can be recharged thousands of times with minimal capacity fade.

Another emerging format is the thin-film battery deposited directly onto the device’s circuit board using sputtering or atomic layer deposition. These batteries are only micrometers thick and can be integrated into the device housing, saving space. In 2022, a team at Rice University demonstrated a flexible lithium-ion microbattery that can withstand repeated bending and surgical handling, making it suitable for implantation.

Supercapacitors as Power Buffers

Supercapacitors (also called ultracapacitors) store energy electrostatically and can deliver short bursts of high current — exactly what is needed for defibrillation (which may require pulses of up to 35 J). By using supercapacitors in parallel with a smaller battery, the battery can be sized for average power consumption while the supercapacitor handles peak demands. This hybrid approach extends battery life and allows for faster charging without stressing the battery chemistry. Medical-grade supercapacitors are now available with biocompatible housings and hermetic seals. In a defibrillator application, the supercapacitor can be charged over a few minutes by an inductive link, and then deliver the shock in milliseconds. Clinical studies are needed, but early prototypes show feasibility.

Clinical Translation and Regulatory Considerations

Bringing any new power technology to market for cardiac devices requires rigorous testing for safety, reliability, and compatibility with the device’s electronics. The U.S. Food and Drug Administration (FDA) and European notified bodies require extensive bench testing, animal studies, and clinical trials. Key safety concerns include:

  • Tissue heating: Inductive and ultrasonic charging must maintain temperature rise below 2°C at the tissue interface to prevent thermal injury. Implantable coils generate eddy currents in tissue, which produce ohmic heating; careful coil design and power limiting are necessary.
  • Electromagnetic interference (EMI): External chargers must not interfere with the device’s sensing or telemetry, nor with other implanted devices (e.g., neurostimulators). The FDA has specific guidelines for EMI testing (ISO 14117).
  • Biocompatibility and hermeticity: All battery and charging components must be encapsulated in a corrosion-resistant, biocompatible material (typically titanium or ceramic) to prevent leakage of toxic chemicals. The implant must maintain hermeticity over years of exposure to body fluids.
  • Patient adherence: Rechargeable systems require patients to regularly perform charging sessions. Failure to do so could lead to premature battery depletion. User-friendly interfaces and automatic charging when the patient sleeps may improve compliance.

Several companies have already initiated clinical trials. For instance, Medtronic has explored an inductive charging system for its Micra™ leadless pacemaker (though no product is yet marketed). Implantable energy-harvesting devices have been tested in short-term animal studies, but no human trials have been completed for a primary cardiac pacing system. The timeline to market for a fully rechargeable or self-powered pacemaker is estimated at 5–10 years, assuming successful completion of pivotal studies.

Potential Impact on Clinical Practice and Patient Outcomes

If these emerging technologies mature, the implications for electrophysiology and cardiology are substantial. Elimination of battery replacement surgeries would reduce the infection rate (currently the highest cause of morbidity in device revisions), lower healthcare costs, and free up operating room time. For children with congenital heart disease who require pacemakers, a rechargeable device could grow with the patient: the battery would not limit lifespan, and the device could be used for decades with only occasional recharger updates. Similarly, patients with ICDs who are at high risk for infections (e.g., those on dialysis or immunosuppression) would benefit greatly from avoiding generator changes.

Moreover, the size reduction allowed by advanced microbatteries could accelerate the adoption of leadless pacemakers, which are currently limited by battery capacity to an average lifespan of 10–12 years. A rechargeable leadless pacemaker could theoretically last indefinitely. This would be especially valuable for older patients and those with complex venous anatomy.

Energy harvesting could eventually eliminate the need for any battery — a “battery-less” pacemaker would be a transformative advance. In such a device, all power would come directly from physiological processes or a wearable external source. A 2020 proof-of-concept study from the University of Michigan demonstrated a system that wirelessly powered a small implant via ultrasound while simultaneously recharging an external wearable battery, creating a closed-loop energy supply chain. Extending that to a fully implantable, battery-free cardiac device remains a long-term goal.

Future Outlook: Integration and Smart Power Management

Looking forward, the most likely scenario is a hybrid system that combines wireless recharging, a small rechargeable battery, and some degree of energy harvesting. The power management integrated circuit (PMIC) will be critical: it must intelligently switch between power sources, maximize efficiency, and protect the battery from overcharging or deep discharge. Advances in ultra-low-power microcontrollers and firmware algorithms will enable the device to adapt its charging schedule to the patient’s activity level and cardiac demand.

A patient might, for example, wear a lightweight inductive vest for 30 minutes each evening while watching television, which would fully charge the device. During the day, a piezoelectric harvester on the device might add 10–20% of the daily energy requirement. If the patient forgets to charge, the system could send a notification to a smartphone and present an audible tone from the external charger. In more advanced versions, the charger could be embedded in a bed pad or pillow, automatically activating when the patient is supine.

Additionally, as artificial intelligence becomes integrated into cardiac devices, power demands may increase. Algorithms for arrhythmia detection, remote monitoring, and adaptive pacing require more computational resources. A sustainable power platform that can scale with future device complexity is essential. Emerging battery chemistries such as lithium-sulfur and lithium-air offer theoretical energy densities 5–10 times higher than lithium-ion — though they are far from implant-grade reliability. Likewise, biofuel cells that use glucose or lactate from the bloodstream are being investigated as a long-term power source, inspired by early work in enzymatic fuel cells.

Conclusion

The era of the sealed, non-rechargeable cardiac device battery is drawing to a close. Advances in wireless power transfer, energy harvesting, and rechargeable micro‑batteries are converging to offer safer, more convenient, and more sustainable alternatives. While engineering challenges remain — particularly around efficiency, safety, patient compliance, and regulatory hurdles — the trajectory is clear. Within the next decade, patients with pacemakers and ICDs may no longer face the prospect of periodic surgeries to replace their device’s battery. Instead, they will benefit from systems that can be recharged non‑invasively, powered by their own body’s motion, or even run indefinitely without any battery at all. The integration of these technologies promises not only to reduce risk and cost but also to improve the quality of life for millions of people living with cardiac implantable electronic devices.